Real-world analysis of more than 294,000 U.S. Veterans aged 65 and older found mNEXSPIKE was associated with a 35.9% lower...
Hubert Bland and Norman Waters strengthen Allucent's specialized expertise and integrated support for life cycle drug developmentCARY, N.C., Nov. 10,...
Boehringer Ingelheim progresses to 6th place in the 2026 Access to Medicine IndexCompany performs above average across all three assessed...
SHELTON, CT / ACCESS Newswire / November 10, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"),...
CAMBRIDGE, MA / ACCESS Newswire / November 10, 2026 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following...
John brings more than 35 years of operational and commercial leadership with extensive experience in bringing medicines to market at...
94% of participants maintained seroresponse five years after a single vaccinationComparable antibody persistence observed in older (65+) and younger adultsData...
LOS ANGELES, Nov. 9, 2026 /PRNewswire/ -- Alaris has secured an investment from Bloomage Biotechnology Corporation (SSE: 688363), a global...
Data from infant immunogenicity and safety trial, and controlled human infection model (CHIM) trial, demonstrate favorable safety profile with encouraging...
Study demonstrated no dose-limiting toxicities and dose-responsive cytokine production consistent with TLR7/8 engagementResults support continued clinical development of INI-4001 as...
Reports third quarter revenue of $1.3 billion, GAAP net income of $0.2 billion and GAAP diluted EPS of $0.38Increases 2026...
Canada becomes the first country to authorize both Moderna's mRNA seasonal influenza vaccine, mFLUSIVA®, and combination influenza and COVID-19 vaccine,...
40-fold lower virus load compared to placebo on Day 2, at the peak of viral replicationExposure-response relationship observed, with greater...
WHO Technical Advisory Group recommends mRNA-1469 for inclusion in efficacy study following encouraging Phase 1 clinical results CAMBRIDGE, MA /...
Initial Phase 1/2 data highlight the potential of Moderna's multiplexed mRNA approach in relapsed or refractory multiple myeloma CAMBRIDGE, MA...
NORTHAMPTON, MA / ACCESS Newswire / November 3, 2026 / When it comes to the flu, misconceptions can make it...
NORTHAMPTON, MA / ACCESS Newswire / November 2, 2026 / Last month, CVS Health, Aetna, and Oak Street colleagues in...
VICAPSYN™, the Company's immune-isolation technology for islet cell transplantation in type 1 diabetes, remains an active asset of Vicapsys and...
This international award, honoring “the best of the best” in medical innovation, represents yet another important external recognition of AI-Immunology™...
Q3 2026: double-digit growth in sales and business EPSFY 2026: guidance upgraded October 30, 2026 Q3 sales growth of 14.3%...